^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    AmoyDx® Essential NGS Panel

    Company:
    Amoy Diagnostics
    Type:
    CE Marked
    Related tests:
    Details
    Evidence

    News

    over1year
    AmoyDx Collaborates with AstraZeneca to Develop a HER2 Companion Diagnostic for Lung Cancer in China (AmoyDx Press Release)
    "Amoy Diagnostics Co., Ltd...today announces that it has entered into a new collaboration agreement with AstraZeneca...Based on the agreement, the AmoyDx® Essential NGS panel, developed by AmoyDx, will be used as a companion diagnostic of ENHERTU® to identify HER2 (ERBB2) mutations in patients with non-small cell lung cancer (NSCLC)....This new agreement further expands the cooperation between the companies with projects in prostate, breast cancer and ovarian cancer ongoing."
    Licensing / partnership
    |
    AmoyDx® Essential NGS Panel
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    2years
    Success of Tepotinib Therapy in Overcoming Resistance to Osimertinib in a Patient with EGFR-Mutant Lung Adenocarcinoma With a Potential Acquired MET Exon 14 Skipping Mutation (IASLC-ACLC 2022)
    "We described a patient with lung adenocarcinoma harboring METex14del as a potential acquired resistance to osimertinib, who responded to subsequent tepotinib therapy. Re-biopsy and re-analysis of genetic profiles should be considered in NSCLC patients who develop osimertinib resistance."
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR T790M • MET exon 14 mutation • MET mutation • EGFR positive
    |
    cobas® EGFR Mutation Test v2 • Oncomine™ Comprehensive Assay v3M • ArcherMET • AmoyDx® Essential NGS Panel
    |
    Tagrisso (osimertinib) • Tepmetko (tepotinib)
    over4years
    Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naive patients with primary lung adenocarcinoma. (PubMed, Int J Clin Exp Pathol)
    "Of the 328 samples, concordance of EGFR between the ARMS assay and NGS was observed in 318 samples (97.0%), and among 32 samples, concordance between ARMS/FISH test and NGS for ALK/ROS1/RET fusion genes was observed in 30 samples (93.8%). Here, we demonstrated that the capture-based ultra-deep targeted sequencing method, which has a LOD of 1% to profile a wide range of actionable variants in surgical specimens of treatment-naive lung adenocarcinoma patients, highlights the need for treatment-naive patients to undergo genomic profiling."
    Journal • Clinical
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • PIK3CA mutation • RET fusion • RET rearrangement
    |
    AmoyDx® Essential NGS Panel